pharma news today obesity drug glp-1 Pipeline Update: August 2025 - Prime Therapeutics Novo Nordisk launches Wegovy weight-loss

This injury causes discomfort and is often associated with weakness in performing daily activities, such as holding a cup of coffee or turning a door handle

PT-141 is administered as a small subcutaneous injection, typically on an as-needed basis rather than as part of a daily dosing protocol

Information Type Review Information Journal of Nutritional Science , Volume 12 , 2023 , e103 Creative Commons This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence ( which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited

Diabetes and obesity both predispose patients to cardiovascular diseases, neurodegenerative diseases, and many other diseases of aging

Stroke benefit and best timing remain uncertain

Append modifier 25 to the E/M code